The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A Randomized, Open-Label, Multicenter Trial for the Safety and Efficacy of Adult Mesenchymal Stem Cells after Acute Myocardial Infarction
Open accessAbstract
Recent studies suggest that the intracoronary administration of bone marrow (BM)-derived mesenchymal stem cells (MSCs) may improve left ventricular function in patients with acute myocardial infarction (AMI). However, there is still argumentative for the safety and efficacy of MSCs in the AMI setting. We thus performed a randomized pilot study to investigate the safety and efficacy of MSCs in patients with AMI. Eighty patients with AMI after successful reperfusion therapy were randomly assigned and received an intracoronary administration of autologous BM-derived MSCs into the infarct related artery at 1 month. During follow-up period, 58 patients completed the trial. The primary endpoint was changes in left ventricular ejection fraction (LVEF) by single-photon emission computed tomography (SPECT) at 6 month. We also evaluated treatment-related adverse events. The absolute improvement in the LVEF by SPECT at 6 month was greater in the BM-derived MSCs group than in the control group (5.9% ± 8.5% vs 1.6% ± 7.0%; P=0.037). There was no treatment-related toxicity during intracoronary administration of MSCs. No significant adverse cardiovascular events occurred during follow-up. In conclusion, the intracoronary infusion of human BM-derived MSCs at 1 month is tolerable and safe with modest improvement in LVEF at 6-month follow-up by SPECT. (ClinicalTrials.gov registration number: NCT01392105).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellikka, P. A., Picard, M. H., Roman, M. J., Seward, J., Shanewise, J. S., et al. (2005) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2005.10.005 · Cited by 11,318
Cited by
Stem Cell Therapies in Clinical Trials: Progress and Challenges
Trounson, A., & McDonald, C. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.06.007 · Cited by 1,468
Stem cell treatment for acute myocardial infarction
Fisher, S. A., Zhang, H., Doree, C., Mathur, A., & Martin-Rendon, E. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006536.pub4 · Cited by 445
Wang, X., Chen, Y., Zhao, Z., Meng, Q., Yu, Y., Sun, J., Yang, Z., Chen, Y., Li, J., Ma, T., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008737 · Cited by 422
Mesenchymal stem cells: Immunomodulatory capability and clinical potential in immune diseases
Zhao, Q., Ren, H., & Han, Z. (2016) · Journal of Cellular Immunotherapy · doi:10.1016/j.jocit.2014.12.001 · Cited by 302
The therapeutic potential of mesenchymal stem cells for cardiovascular diseases
Guo, Y., Yu, Y., Hu, S., Chen, Y., & Shen, Z. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2542-9 · Cited by 298
Metadata
- Authors
- Lee, J.-W., Lee, S.-H., Youn, Y.-J., Ahn, M.-S., Kim, J.-Y., Yoo, B.-S., Yoon, J., Kwon, W., Hong, I.-S., Lee, K., Kwan, J., Park, K. S., Choi, D., Jang, Y. S., & Hong, M. K.
- Venue
- Journal of Korean Medical Science
- Publisher
- Korean Academy of Medical Sciences
- Published
- 2014
- Volume
- 29
- Issue
- 1
- Pages
- 23
- ISSN
- 1011-8934 (ISSN-L)
- 1598-6357
- OpenAlex
- W1964277071
- Cited by
- 179
- References
- 1
- FWCI
- 7.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized, Open-Label, Multicenter Trial for the Safety and Efficacy of Adult Mesenchymal Stem Cells after Acute Myocardial Infarction. https://app.cochat.ai/papers/10.3346/jkms.2014.29.1.23
- The paper
- Lee, J.-W., Lee, S.-H., Youn, Y.-J., Ahn, M.-S., Kim, J.-Y., Yoo, B.-S., Yoon, J., Kwon, W., Hong, I.-S., Lee, K., Kwan, J., Park, K. S., Choi, D., Jang, Y. S., & Hong, M. K. (2014). A Randomized, Open-Label, Multicenter Trial for the Safety and Efficacy of Adult Mesenchymal Stem Cells after Acute Myocardial Infarction. Journal of Korean Medical Science. https://doi.org/10.3346/jkms.2014.29.1.23
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.